Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results

M. R.A. Khairi, R. D. Altman, G. P. DeRosa, J. Zimmermann, R. K. Schenk, C. C. Johnston

Research output: Contribution to journalArticlepeer-review

118 Scopus citations


Subjects (109) with symptomatic Paget's disease of bone were treated with 5, 10, or 20 mg of sodium etidronate (EHDP)/kg body weight/day for 6 to 24 mth. Significant decreases in serum alkaline phosphatase and urinary hydroxyproline were noted after 6 mth of therapy; no significant further improvement resulted after prolonged therapy. Some patients maintained biochemical remission after withdrawal of EHDP but others showed a relapse, related primarily to the pretreatment severity. Clinical improvement was noted in 61% of the patients. Similar findings were seen after a second course of EHDP. No side-effects were noted in patients treated with 5 mg of EHDP/kg body weight/day. In patients treated with 10 or 20 mg of EHDP/kg body weight/day, severe diarrhea, bone pain, and nontraumatic fractures were noted in 3, 13, and 12 patients respectively. Quantitative histomorphometry showed mineralization delay in patients receiving 10 or 20 mg of EHDP/kg body weight/day but not in those receiving 5 mg/kg body weight/day. Five milligrams of EHDP/kg body weight/day was effective and appears to be safer than the higher doses.

Original languageEnglish (US)
Pages (from-to)656-663
Number of pages8
JournalUnknown Journal
Issue number6
StatePublished - Jan 1 1977

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results'. Together they form a unique fingerprint.

Cite this